1. Record Nr. UNINA9910808374903321

Autore	Lednicer Daniel
Titolo	Antineoplastic drugs : organic synthesis / / Daniel Lednicer
Pubbl/distr/stampa	Chichester, England : , : Wiley, , 2015 ©2015
ISBN	1-118-89256-9 1-118-89255-0 1-118-89257-7
Descrizione fisica	1 online resource (230 p.)
Classificazione	SCI007000
Disciplina	616.994061
Soggetti	Antineoplastic agents
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references at the end of each chapters and indexes.
Nota di contenuto	Title Page; Copyright Page; Contents; Preface; Introduction; Chapter 1 Alkylating Agents; 1.1 bis-Chloroethyl Amines; 1.2 Several Other Chloroethyl Agents; 1.3 Platinum-Based Antineoplastic Agents; 1.4 Miscellaneous Alkylating Agents; References; Chapter 2 Antimetabolites; 2.1 Introduction; 2.2 Folate Antagonists; 2.2.1 Compounds with Glutamate Side Chain; 2.2.2 Compounds Lacking the Glutamate Moiety; 2.2.3 Methoxylated Benzenes; 2.3 Pyrimidines and Purines; 2.3.1 Aglycones; 2.3.2 Saccharide-Linked Compounds; References; Chapter 3 Hormone Blocking Anticancer Drugs; 3.1 Introduction 3.2 Estrogen Antagonists3.2.1 Estrogen Antagonists; 3.2.2 Aromatase Inhibitors; 3.3 Androgen Antagonists; 3.3.1 Non-steroidal Antian drogens; 3.3.2 Steroid Androgen Antagonists; References; Chapter 4 Topoisomerase Inhibitors; 4.1 Introduction; 4.2 Anthracyclines; 4.3 Anthraquinones and Anthrapyrazoles; 4.3.1 Anthraquinones with Two Aminoalkyl Side Chains; 4.3.2 Anthraquinones with a Fused Pyrazole Ring; 4.3.3 Heterocyclic Anthraquinones; 4.4 Camptothecins; 4.4.1 Compounds from Modified Camptothecin; 4.4.2 Camptothecins by Total Synthesis; 4.5 Miscellaneous Topoisomerase Inhibitors; References Chapter 5 Mitotic Inhibitors5.1 Introduction; 5.2 Taxanes; 5.3 Wholly

	Synthetic Compounds; 5.3.1 Carbocyclic Compounds; 5.3.2 Peptide-Like Inhibitors; 5.3.3 Monocyclic Heterocyclic Inhibitors; 5.3.4 Bicyclic 5:6 Heterocyclic Inhibitors; 5.3.5 Bicyclic 6:6 Heterocyclic Tubulin Inhibitors; References; Chapter 6 Matrix Metalloproteinase Inhibitors; 6.1 Introduction; 6.2 Hydroxamates; 6.2.1 Agents with an Isobutyl Moiety; 6.2.2 A Thiomorpholine; 6.2.3 Sulfamates; 6.2.4 Miscellaneous Compounds; References; Chapter 7 Histone Deacetylase Inhibitors; 7.1 Introduction; 7.2 Hydroxamates 7.3 PhenylenediaminesReferences; Chapter 8 Enzyme Inhibitor, Part I, Tyrosine Kinases; 8.1 Introduction; 8.2 Epidermal Growth Factor Inhibitors; 8.3 VEGF; 8.3.1 Fused Ring Compounds; 8.3.2 Linear Arrays; 8.4 SRC Nonreceptor Tyrosine Kinase; 8.5 PDGF; 8.6 EGF; 8.7 Other TKI; 8.7.1 Linear Arrays; 8.7.2 Compounds with Two Fused Rings; 8.8 Janus Kinase Inhibitors; References; Chapter 9 Enzyme Inhibitors: Part II Additional Targets; 9.1 Serine-Threonine Kinase Inhibitors; 9.2 Additional Enzyme Inhibitors; 9.2.1 Farnesyl Transferase Inhibitors; 9.2.2 Cyclin-Dependent Kinase Inhibitors 9.2.3 Proteasome Inhibitors9.2.4 PARP Inhibitors; 9.2.5 Various Other Enzyme Inhibitors; References; Chapter 10 Miscellaneous Antineoplastic Agents; 10.1 Acyclic; 10.2 Monocyclic; 10.3 Two Linked Rings; 10.4 Rings on a Chain; 10.4.1 Two Rings; 10.4.2 Four and More Rings; 10.5 Fused Rings; 10.5.1 Indoles; 10.5.2 Purine-Like; 10.5.3 Tetralins and a Naphthalene; 10.5.4 Etc.; References; Appendix A; Index of Heterocycle Syntheses; Subject Index; EULA
Sommario/riassunto	"Antineoplastic Drugs: Organic Syntheses is written to appeal to organic and medicinal chemists in industry and academia. It is beneficial to those composing grant proposals for NCI and related organizations"--